Population Pharmacokinetics of Tigecycline: A Systematic Review

Abstract Although tigecycline is widely used in clinical practice, its efficiency and optimal dosage regimens remain controversial. The purpose of this article was to help guide tigecycline dosing in different patient subpopulations through comparing the published population pharmacokinetic models of tigecycline, as well as summarizing and determining the potential covariates that markedly influence tigecycline pharmacokinetics. In this review, literature was systematically searched from the PubMed database from inception to March 2022. The articles focusing on population pharmacokinetics for tigecycline in healthy volunteers or patients were included; finally, a total of eight studies were included in this review. NONMEM methods were used in five studies to generate the population pharmacokinetic models. Tigecycline pharmacokinetics were mostly described by a two-compartment model in these included studies. Estimated clearance and volumes of distribution of tigecycline at steady state (Vss) varied widely in different target patient populations, with a range of 7.5–23.1 L/h and 212.7–1087.7 L, respectively. Body-weight and creatinine clearance were the most important predictors of clearance in these studies, while other predictors include age, gender, bilirubin and aspartate aminotransferase. In conclusion, this review showed the large variability of tigecycline population pharmacokinetics, which can provide guide dosing in different target populations. For clinicians, the individual dosing adjustment should be based not only on the indication and pathogen susceptibility but also on the potential important predictors. However, more studies were needed to confirm the necessity of modified dosage regimens in different patient subpopulations.

• Publication year

  2022

• Venue

  Drug Design, Development and Therapy

• Publication date

  2022-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/DDDT.S365512PMID 35747442PMCID 9211078
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OUP accepted manuscript

  2022cited by this paper
• Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections.

  2022cited by this paper
• The Impact of C Reactive Protein in Prediction of the Outcome in Infective Endocarditis

  2021cited by this paper
• Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia

  2021cited by this paper
• Risk Factors for Tigecycline-Associated Hypofibrinogenemia

  2021cited by this paper
• Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

  2021cited by this paper
• Population pharmacokinetics and exposure‐response analysis of tigecycline in patients with hospital‐acquired pneumonia

  2020influential reference
• An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults

  2020cited by this paper
• Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)

  2020cited by this paper
• Safety and Efficacy of Tigecycline in ICU Patients Based on Therapeutic Drug Monitoring.

  2020cited by this paper
• Tigecycline

  2019cited by this paper
• The influence of age on the clinical efficacy of tigecycline in severely ill patients.

  2019cited by this paper
• Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

  2018cited by this paper
• Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock

  2018cited by this paper
• The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis

  2017cited by this paper
• A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding.

  2017cited by this paper
• Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections

  2017influential reference
• Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.

  2016cited by this paper
• The role of tigecycline in the treatment of infections in light of the new black box warning

  2014cited by this paper
• High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria

  2014cited by this paper
• Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults.

  2014cited by this paper
• Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia

  2013cited by this paper
• Pretreatment data is highly predictive of liver chemistry signals in clinical trials

  2012cited by this paper
• Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function

  2012cited by this paper
• How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics.

  2012cited by this paper
• Effectiveness and safety of tigecycline: focus on use for approved indications.

  2012cited by this paper
• Excess deaths associated with tigecycline after approval based on noninferiority trials.

  2012cited by this paper
• Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia

  2010influential reference
• Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

  2010cited by this paper
• Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.

  2009cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline

  2009cited by this paper
• Population Pharmacokinetics of Tigecycline in Healthy Volunteers

  2007cited by this paper
• Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections

  2006influential reference
• Tigecycline.

  2005cited by this paper
• Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

  2005cited by this paper
• Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects

  2005influential reference
• Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

  2004cited by this paper
• Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

  2000cited by this paper
• Drug design

  1992cited by this paper

• Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae.

  2026cites this paper
• A One Health Perspective on the Plasmid Backbone Preference and Evolutionary Adaptation of tmexCD-toprJ in Klebsiella spp.

  2026cites this paper
• Standard dose could be better! A multicenter study of tigecycline in patients with liver failure

  2025cites this paper
• Molecular Analysis of Tigecycline Resistance in Carbapenem-Resistant Enterobacterales (CRE) in Mthatha and Surrounding Hospitals

  2025cites this paper
• A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection

  2025cites this paper
• Population Pharmacokinetics of Tigecycline and Implications for Individualized Therapy Optimization: A Systematic Review

  2025cites this paper
• Population Pharmacokinetics of Tigecycline in Critically Ill Patients and Optimal Dosage Regimens With Dose Simulations Based on Infection Type and Renal Function

  2025cites this paper
• Systematic Review of Linezolid Population Pharmacokinetics in Pediatric: Models, Covariates, and Dosing Implication

  2025cites this paper
• A Perspective on Combination of Antibiotic Therapy for Extensively Drug-Resistance Bacterial Infections

  2025cites this paper
• Repurposing antibiotics: A dual-action approach against bacteria-induced cancer

  2025cites this paper
• Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling

  2024cites this paper
• Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential

  2024cites this paper
• Influence of continuous renal replacement therapy on the plasma concentration of tigecycline in patients with septic shock: A prospective observational study

  2023cites this paper
• An "ON-OFF" fluorescent sensor based on a novel zinc-based flower-like structured metal-organic framework for sequential detection of deferasirox and tigecycline.

  2023cites this paper
• Tigecycline Immunodetection Using Developed Group-Specific and Selective Antibodies for Drug Monitoring Purposes

  2023cites this paper